Beijing Jiluntai's ¹⁷⁷Lu-JLT003 Injection Receives IND Approval for Treatment of Integrin αvβ3-Positive Malignant Tumors

Beijing Jiluntai Pharmaceutical Co., Ltd. has recently achieved progress in radiopharmaceutical R&D. Its self-developed Class 1 innovative therapeutic radiopharmaceutical ¹⁷⁷Lu-JLT003 Injection (generic name: ¹⁷⁷Lu-AB-3PRGD2) has obtained the Clinical Trial Approval (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), intended for the treatment of integrin αvβ3-positive malignant tumors. ¹⁷⁷Lu-AB-3PRGD2 is a therapeutic radiopharmaceutical targeting integrin αvβ3. Integrin αvβ3 is highly expressed on various solid tumor cells and tumor neovascular endothelial cells, while showing low expression in normal tissues, a characteristic that...

2026-09-01

Russian scientists use 3D-printed tungsten grid to improve X-ray imaging quality, potentially reducing patient radiation exposure

The press service of the Russian Ministry of Education and Science recently stated that a Russian research team has used 3D printing technology to manufacture a tungsten-based anti-scatter grid for X-ray machines, with partition thickness only one-third that of similar products. The researchers believe this achievement could help reduce patient radiation exposure during X-ray examinations while maintaining medical image quality. During X-ray imaging, some rays scatter after passing through human tissue, creating background noise that weakens image contrast. Clinical equipment typically suppresses such interference through anti-scatter grids. Traditional anti-scatter grids are mostly made of lead, but lead has low mechanical strength and imposes high requirements on processing techniques, resulting in...

2026-09-01

Bayer Presents Phase III Data for Iodine-124 PET Tracer: High Sensitivity Shown in Cardiac Amyloidosis Diagnosis

At the 2026 European Society of Cardiology Congress, Bayer presented results from the Phase III REVEAL study of its investigational PET radiotracer iodine-124 evuzamitide (I-124 evuzamitide). Data showed that the tracer met the study's primary endpoints in diagnostic sensitivity and specificity when used for imaging in patients with suspected cardiac amyloidosis. The REVEAL study, sponsored by Brigham and Women's Hospital, is a multicenter, open-label, single-arm Phase III clinical trial conducted at 18 sites in the United States, enrolling 170 adult patients with suspected cardiac amyloidosis. Following a single intravenous injection of I-124 evuzamitide, subjects underwent cardiac and...

2026-09-01

Defence Therapeutics Expands Radiopharmaceutical R&D Program to Evaluate Alpha and Beta Emitter Applications

MONTREAL, Quebec, Canada — Biotechnology company Defence Therapeutics Inc. recently announced the expansion of its radiopharmaceutical R&D program to include α and β radioisotopes in its evaluation scope, further validating the application potential of its proprietary Accum® technology in precision oncology. Defence Therapeutics is a publicly traded biotechnology company developing next-generation oncology treatments centered on its Accum® precision drug delivery platform. The company stated that the Accum® technology is designed to facilitate the entry of drug payloads into the intracellular compartment, thereby improving delivery efficiency. This expansion of the radiopharmaceutical program...

2026-09-01

CNNC Headway's 13C-Urea Synthesis Control Method Patent Wins China Patent Excellence Award

On August 28, the China National Intellectual Property Administration officially released the decision on the 26th China Patent Award, and CNNC Headway's invention patent "A 13C-Urea Synthesis Control Method" won the China Patent Excellence Award. This patented technology addresses key technical bottlenecks in the batch production of carbon [13C]-urea API, establishing a set of synthesis control methods that provide technical support for the large-scale and stable production of the relevant API. The application of this technology helps enhance the self-sufficiency capability of the domestic urea [13C] breath diagnostic industry chain. CNNC Headway has long been deeply engaged in the breath diagnostic field, with sustained investment in innovative R&D, quality control, clinical adaptation, and industry chain layout...

2026-09-01

Japanese research team visualizes cellular metabolic changes during fracture healing using hyperpolarized MRI

August 21, 2026, Gifu Pharmaceutical University and Gifu University announced that a multi-institutional Japanese research team successfully visualized changes in the redox state of skeletal progenitor cells during fracture healing in living mice using hyperpolarized magnetic resonance imaging technology. The findings were published online on August 15, 2026, in the British academic journal *npj Imaging*. The study was led by Takuya Kubo, a graduate student in the Department of Pharmacology at Gifu Pharmaceutical University, Professor Eiichi Hinoi, and related research teams at Gifu University, in collaboration with the University of Tokyo, Osaka University, the Research Institute of National Rehabilitation Center for Persons with Disabilities, and other institutions. After a fracture occurs, a tissue called a...

2026-08-31

Portable X-ray Equipment in the U.S. Used for On-Site Assessment of American Football Injuries

As the 2026–2027 American football season approaches, team training camps, player evaluations, and medical support preparations are getting underway. Given the risk of acute sports injuries from the high-intensity physical contact in American football, portable X-ray equipment is being used to improve the efficiency of injury assessment on the sidelines and at training facilities. According to reports, American football players are prone to fractures, sprains, joint dislocations, and contusions. Relevant data indicates that the incidence of severe injuries such as fractures, dislocations, and contusions in this sport is higher than in other sports, with fractures accounting for approximately 10% of all football injuries. Such injuries typically require X-ray radiography to aid diagnosis, but traditional X-ray machines are bulky and fixed in place, usually requiring use in facilities with appropriate shielding. Injured players often need to be transported to the radiology department for examinations, which may delay diagnosis and treatment decisions.

2026-08-31

Chonnam National University Hospital in Hwasun, South Korea, Adopts Deepnoid's Chest X-ray AI Interpretation Solution "M4CXR"

Deepnoid announced on August 31 that it has signed a supply contract with Chonnam National University Hospital in Hwasun, South Korea, to provide the hospital with its AI-based chest X-ray preliminary opinion generation solution, M4CXR. This contract is part of the "AI Medical System Support Project for Regional Responsible Medical Institutions" promoted by the Ministry of Health and Welfare of South Korea. Chonnam National University Hospital in Hwasun plans to improve the work efficiency of medical staff in interpreting chest X-ray images and further enhance the quality of medical services through the introduction of M4CXR. A representative from the Hwasun branch of Chonnam National University Hospital stated that introducing a generative AI-based image interpretation support system is of great significance for improving the quality of public medical services...

2026-08-31

Assam, India, Plans to Introduce Proton Beam Therapy for Cancer Treatment at a Public Hospital

Cancer treatment capabilities in Assam, India, are set to be upgraded. Assam Chief Minister Himanta Biswa Sarma announced that the state cabinet has approved the introduction of a proton beam therapy system at Gauhati Medical College Hospital. Once the project is completed, Assam will become the third region in India to offer proton beam therapy, and the hospital will be the first public hospital in India to be equipped with this technology. Currently, proton beam therapy is already in use at the Tata Memorial Centre in Mumbai and the Apollo Proton Cancer Centre in Chennai. The facility planned at Gauhati Medical College Hospital will become the third such treatment center in India. Proton beam therapy is an advanced form of radiotherapy used to treat cancer and certain non-cancerous tumors. Unlike conventional radiation therapy, which typically uses X-rays, proton therapy delivers precise irradiation to the tumor area using high-energy positively charged particles—protons. As proton beams enter the body, they release energy, causing DNA damage to cells. Healthy cells generally possess some capacity for repair, whereas cancer cells are less able to repair themselves, thereby inhibiting their growth and proliferation and helping to destroy tumor tissue.

2026-08-31

Construction of Radiotherapy Room at Sao San Tun Hospital in Taunggyi, Myanmar, Approximately 80% Complete

On August 30, 2026, the Chief Minister of Shan State, Myanmar, U Sai Tin Soe, accompanied by relevant officials, inspected the construction of the radiotherapy room at Sao San Tun Hospital in Taunggyi. The radiotherapy room is a single-story reinforced concrete building with a floor area of 95 feet × 52 feet, and the project is currently approximately 80% complete. During the inspection, officials from the building department reported on the project's construction progress, and the Chief Minister gave instructions on subsequent work and coordinated the necessary support. On the same day, the Chief Minister and his delegation also inspected the site for a planned five-story expansion building at the hospital and discussed related construction arrangements. Once completed, the radiotherapy room will be used to enhance the hospital's medical service capacity for radiotherapy-related care. ...

2026-08-31

Leo Cancer Care and GE HealthCare Announce Collaboration to Advance Upright Radiotherapy Workflow Integration

Leo Cancer Care recently announced a commercial collaboration with GE HealthCare, focusing on GE HealthCare's advanced imaging solutions and intelligent radiotherapy software, with plans to apply related technologies to Leo Cancer Care's future upright radiotherapy systems to streamline patient and data workflows from simulation to treatment delivery. Under the collaboration framework, the two parties will explore integration pathways between GE HealthCare's intelligent radiotherapy software iRT and Leo Cancer Care's future upright radiotherapy solutions. iRT is an AI-assisted software developed for radiotherapy settings, primarily used to connect information, workflows, and applications across different systems, helping healthcare institutions simplify complex processes, enable patients to enter radiotherapy more promptly, and reduce clinician burden.

2026-08-30

Radiology Partners to Acquire Everlight, Expanding International Teleradiology Services

U.S. radiology services provider Radiology Partners has agreed to acquire Everlight Radiology, planning to expand its teleradiology diagnostic services into markets including the United Kingdom, Ireland, Australia, New Zealand, and South Africa. Founded in 2006, Everlight employs a "follow-the-sun" teleradiology service model, leveraging radiologists across different time zones to provide continuous imaging diagnostic coverage. The company currently has over 800 radiologists, operates in more than 40 countries, and completes over 2.5 million imaging examination reports annually for more than 340 client institutions. Radiology Partners is headquartered in Nashville, Tennessee, USA,...

2026-08-30

Blueprint for Proton Therapy Center in Southeastern Busan, South Korea Unveiled to Address Regional Gap in Cancer Treatment Resources

The blueprint for the proton therapy center at the Southeastern Regional Nuclear Medicine Center in Gijang-gun, Busan, South Korea, was recently unveiled. The project is expected to help bridge the gap in cancer treatment resources between the Seoul metropolitan area and non-capital regions, and to promote the application of proton accelerators in high-tech industries. According to information from Gijang-gun, Busan, and the Southeastern Regional Institute of Radiation Medicine on August 29, the Busan Institute of Science and Technology Higher Education recently published a service report titled "Establishment of Promotion Strategy and Implementation Plan for the Southeastern Proton Therapy Center," which includes the construction blueprint and feasibility analysis of the center. The Southeastern Regional Institute of Radiation Medicine is advancing related preparatory work in response to the research and development review by the Ministry of Science and ICT in the second half of this year...

2026-08-30

China Isotope & Radiation Plans to Invest RMB 400 Million in Zhejiang Nuclear Technology Application Industry Fund

China Isotope & Radiation Corporation announced on August 28 that its board of directors has approved entering into a partnership agreement with CNNC, CNNC Capital, CNNC Fund, National Industry Investment Fund, Zhejiang Venture Capital Guidance Fund, Jiaxing Changchuang Industrial Investment, and Haiyan County State-owned Capital Investment to jointly establish CNNC (Zhejiang) Nuclear Technology Application Industry Investment Fund Partnership (Limited Partnership). According to the announcement, the fund will be registered in Jiaxing City, Zhejiang Province, with partners intending to subscribe to a total capital contribution of RMB 3 billion. Among them, China Isotope & Radiation plans to contribute RMB 400 million from internal resources, accounting for 13.33% of the fund's total subscribed capital; CNNC Fund, as the general partner, plans to contribute RMB 30 million, accounting for 1%; the National...

2026-08-29

CNNC Changchun Nuclear Medicine Base Obtains Production License

On August 28, the Jilin Provincial Drug Administration approved and issued the "Radiopharmaceutical Production License" to Changchun Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as "Changchun Hi-Tech"), a subsidiary of Atomic Hi-Tech under China Isotope & Radiation Corporation (CIRC). The acquisition of this license marks that Changchun Hi-Tech is now fully qualified for the production of technetium-labeled drugs. Radiopharmaceuticals are characterized by short half-lives, high transportation requirements, and strict time sensitivity. Long-distance transportation not only increases transportation and time costs but also poses greater challenges to the stability and timeliness of clinical medication. With the production qualification, Changchun Hi-Tech will be able to complete the production and distribution of technetium-labeled drugs locally in Jilin Province, which will help improve the clinical use of nuclear medicine in the Northeast region...

2026-08-29

Thor Medical Advances AlphaOne Commercial Production in H1, Completes First Customer Deliveries of Lead-212 Isotope

Thor Medical ASA, a supplier of high-purity isotopes to the radiopharmaceutical industry, announced its H1 2026 results on August 28. The company stated that its AlphaOne facility has completed mechanical construction on time and on budget and has entered commercial production, marking the start of a new phase focused on scaling output, increasing customer deliveries, and growing revenue. Thor Medical CEO Jasper Kurth said that with the completion of the first customer product deliveries from AlphaOne, the company has established a solid commercial foundation in a rapidly growing market, and the next step is to advance the execution plan around capacity expansion, customer deliveries, and revenue growth to support the development of next-generation precision cancer therapies...

2026-08-28

South Korea's Medical Radiation Examinations Exceed 430 Million Annually, with CT Scans Accounting for 67.1% of Radiation Dose

According to the "2025 National Medical Radiation Assessment Yearbook" released by the Korea Disease Control and Prevention Agency on August 28, South Koreans underwent a total of 431.59 million medical radiation examinations last year, averaging 8.4 examinations per person. Over the past five years, the number of medical radiation examinations in South Korea has continued to rise, with last year's figure increasing by 4.6% year-on-year and 29.6% compared to 2021. The report shows that the collective radiation dose from medical radiation examinations in South Korea increased from 136,804.73 person-sieverts in 2021 to 167,659.18 person-sieverts last year, an increase of 22.6%. On a per capita basis, the radiation dose rose from 2.64 millisieverts to 3.24 millisieverts. The Korea Disease Control and Prevention Agency stated that with advances in medical technology, an aging population, and growing demand for health checkups, the use of medical radiation examinations in public healthcare services continues to expand.

2026-08-28

Russian Thorium-Based Radiopharmaceuticals Expected Within 1-2 Years

On August 27, Igor Korobko, Professor of the Russian Academy of Sciences and Director of the Department of Medical and Scientific Development in Healthcare of the Russian Ministry of Health, stated at the Technoprom Forum held in Novosibirsk that thorium-based drugs for precision radionuclide therapy of tumors are expected to become available in Russia within the next 1 to 2 years. Korobko noted that tumor treatment still requires support from more available isotopes. For example, when patients develop resistance to actinium-related therapies, clinical practice necessitates the use of different isotopes for treatment. He stated that Russia is advancing the development of related therapies domestically and expects to have thorium-based drugs within the next year or two. Currently, actinium-225 is considered one of the more promising radionuclides...

2026-08-28

Russia Plans to Complete Development of First Domestic Proton Beam Therapy Cyclotron by 2027

Russian scientists plan to complete the development of the country's first domestically produced proton beam therapy cyclotron by 2027, with commissioning to begin in the same year. This progress was announced by Sergey Gertzog, CEO of the Russian National Institute of Electronics and Atomic Energy (NIIEFA), at the recent Technoprom forum held in Novosibirsk. A proton beam therapy cyclotron is a type of charged particle accelerator that uses magnetic and electric fields to accelerate protons to high-energy states, reaching speeds of one-half to two-thirds the speed of light. The accelerated proton beam can target cancerous tumor areas with relative precision for oncological treatment. According to the schedule outlined in Gertzog's report...

2026-08-28

Russia Advances Radiopharmaceutical Development, Plans to Expand into Diagnostics and Treatment of Heart Disease and Other Conditions

Rosatom is developing radiopharmaceuticals for the diagnosis and treatment of neurodegenerative diseases, heart disease, and rheumatic conditions, further expanding the application of radionuclide technology in medicine. During the 13th International Technology Development Forum Technoprom-2026 held in Novosibirsk, Sergei Surov, Director of the Department of Radionuclide Products and Nuclear Medicine at Rosatom's Science Division, stated that the company is advancing the development of these drugs. Radiopharmaceuticals typically contain radioactive isotopes, i.e., radionuclides, and are currently used in medicine primarily for the diagnosis and treatment of various cancers. Surov noted that the new development directions mean...

2026-08-28

Russia and Egypt Plan to Cooperate on Construction of Nuclear Medicine Center and Radiopharmaceutical Plant

Alexey Likhachev, CEO of Rosatom, recently stated that Russia and Egypt are expanding cooperation in non-energy nuclear technologies, with one of Egypt's key priorities being the construction of a high-performance nuclear medicine center based on a research reactor. According to reports, the project will adopt a comprehensive approach, including a radiopharmaceutical production plant, isotope production facilities, and modern diagnostic systems based on PET and SPECT technologies. Some diagnostic systems will use Russian equipment. Once completed, the project is expected to conduct up to 30,000 diagnostic examinations annually and provide treatment services for 400 patients. Construction of the medical facility is expected to begin as early as 2027...

2026-08-28